SCHEMBL23068612

SCHEMBL23068612

CCCCCC=CCC=CCCCCCCCC(=O)OCCC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.75
ALDH1A1 P00352 6/20 0.73
MAPT P10636 1/20 0.73
THRB P10828 1/20 0.73
CNR1 P21554 1/20 0.73
CYP3A4 P08684 2/20 0.65
ALOX15 P16050 2/20 0.65
TSHR P16473 2/20 0.65
HSD17B10 Q99714 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
F7 P08709 4/20 0.63
F3 P13726 4/20 0.63
KDM4E B2RXH2 3/20 0.63
PPARG P37231 3/20 0.63
PPARD Q03181 3/20 0.63
PPARA Q07869 3/20 0.63
FFAR1 O14842 3/20 0.63
FABP3 P05413 2/20 0.63
PTGS1 P23219 2/20 0.63
DUSP3 P51452 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8982650 1.00 MGLL (0.75) MGLLALDH1A1MAPTTHRBCNR1
SCHEMBL423106 1.00 MGLL (0.75) MGLLALDH1A1MAPTTHRBCNR1
SCHEMBL29562070 1.00 MGLL (0.75) MGLLALDH1A1MAPTTHRBCNR1
SCHEMBL23068611 1.00 MGLL (0.75) MGLLALDH1A1MAPTTHRBCNR1
SCHEMBL8982652 1.00 MGLL (0.75) MGLLALDH1A1MAPTTHRBCNR1
Iodide SCHEMBL28774881 0.98 MGLL (0.73) MGLLALDH1A1MAPTTHRBCNR1
Methane SCHEMBL28105583 0.98 MGLL (0.73) MGLLALDH1A1MAPTTHRBCNR1
SCHEMBL3660029 0.95 MGLL (0.82) MGLLALDH1A1MAPTTHRBCNR1
SCHEMBL7639501 0.95 MGLL (0.77) MGLLALDH1A1MAPTTHRBCNR1
SCHEMBL3660027 0.95 MGLL (0.82) MGLLALDH1A1MAPTTHRBCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122075746-A Microsphere composition, preparation method thereof and application thereof in preparation of contrast agent and medicine 2026-05-26 CN claimed
EP-4359531-A1 METHODS FOR IN VIVO EDITING OF A LIVER GENE Intellia Therapeutics, Inc. (US) 2024-05-01 EP claimed
EP-4352225-A1 MODIFIED GUIDE RNAS COMPRISING AN INTERNAL LINKER FOR GENE EDITING Intellia Therapeutics, Inc. (US) 2024-04-17 EP claimed
WO-2022271780-A1 METHODS FOR IN VIVO EDITING OF A LIVER GENE INTELLIA THERAPEUTICS, INC. (US) 2022-12-29 WO claimed
WO-2022261292-A1 MODIFIED GUIDE RNAS COMPRISING AN INTERNAL LINKER FOR GENE EDITING INTELLIA THERAPEUTICS, INC. (US) 2022-12-15 WO claimed
US-20210068444-A1 CANNABINOID COMPOSITIONS WITH IMPROVED ORGANOLEPTIC AND THERAPEUTIC PROPERTIES, METHOD OF PRODUCTION, AND USE THEREOF CALIFORNIA AMBER INC. 2021-03-11 US claimed
WO-2026102260-A1 CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3) EDITAS MEDICINE, INC. (US) 2026-05-15 WO disclosed
WO-2026102108-A1 DNA PRODUCTION METHODS FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) 2026-05-15 WO disclosed
EP-4655402-A1 NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) Providence Therapeutics Holdings Inc. (CA) 2025-12-03 EP disclosed
EP-4638748-A2 COMPOSITIONS AND METHODS FOR PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) EDITING Intellia Therapeutics, Inc. (US) 2025-10-29 EP disclosed
EP-4619438-A2 COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES Regeneron Pharmaceuticals, Inc. (US) 2025-09-24 EP disclosed
EP-4561636-A1 COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE Regeneron Pharmaceuticals, Inc. (US) 2025-06-04 EP disclosed
EP-4522726-A1 VECTORS AND METHODS FOR IN VIVO ANTIBODY PRODUCTION Regeneron Pharmaceuticals, Inc. (US) 2025-03-19 EP disclosed
EP-4143304-A2 METHODS OF IN VITRO CELL DELIVERY Intellia Therapeutics, Inc. (US) 2023-03-08 EP disclosed
CN-115516090-A TREM compositions and uses thereof 旗舰先锋创新VI有限责任公司 2022-12-23 CN disclosed
WO-2022261292-A1 MODIFIED GUIDE RNAS COMPRISING AN INTERNAL LINKER FOR GENE EDITING INTELLIA THERAPEUTICS, INC. (US) 2022-12-15 WO disclosed
CN-115362256-A Compositions and methods for kallikrein (KLKB 1) gene editing 因特利亚治疗公司 2022-11-18 CN disclosed
EP-4073249-A1 MODIFIED GUIDE RNAS FOR GENE EDITING Intellia Therapeutics, Inc. (US) 2022-10-19 EP disclosed
WO-2021050786-A1 CANNABIN OID COMPOSITIONS WITH IMPROVED ORGANOLEPTIC AND THERAPEUTIC PROPERTIES, METHOD OF PRODUCTION, AND USE THEREOF CALIFORNIA AMBER INC. (US) 2021-03-18 WO disclosed
US-20210068444-A1 CANNABINOID COMPOSITIONS WITH IMPROVED ORGANOLEPTIC AND THERAPEUTIC PROPERTIES, METHOD OF PRODUCTION, AND USE THEREOF CALIFORNIA AMBER INC. 2021-03-11 US disclosed